Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of SPD8 subcutaneous injection vial and Pralia in healthy postmenopausal women
jRCT2031260368Phase 1Completed
- Sponsor
- GlycoNex
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of denosumab in osteoporosis (2 arms), sponsored by GlycoNex. Primary endpoints: Cmax and AUC0-t. Started May 2023; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2031260368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260368.